Comparison the Clinical Outcomes of Progestin-Primed Ovarian Stimulation during Follicular Period and Mild-stimulation in Patients with Diminished Ovarian Reserve
-
摘要:
目的 卵巢储备功能下降(DOR)患者行试管婴儿助孕过程中,比较2种不同促排卵方案(卵泡期高孕激素下促排和微刺激方案)的助孕临床结局。 方法 回顾性分析2021年4月至2022年4月在昆明医科大学第一附属医院行第1代及第2代试管婴儿(IVF/ICSI)辅助生殖助孕治疗的DOR患者,共纳入294个周期,分为2组(A组:PPOS组,B组:微刺激组),比较2组患者在促排卵过程中的用药情况、胚胎情况及妊娠结局。 结果 A组Gn启动剂量、Gn总量、Gn天数、夜针剂量显著高于B组(P < 0.05);A组HCG日LH低于B组( P < 0.05);A组获卵数、获胚数、优胚数均高于B组( P < 0.05)。 结论 从临床结局看PPOS组临床结局优于微刺激组。 Abstract:Objective To compare the clinical outcomes of PPOS protocal and mild-stimulation protocal in patients with diminished ovarian reserve function during assisted reproduction and pregnancy. Methods Patients with DOR who underwent the first and second generation of test-tube babies(IVF/ICSI) in the First Affiliated Hospital of Kunming Medical University from April 2021 to April 2022 were retrospectively analyzed. A total of 294 cycles were included and divided into 2 groups(group A: PPOS group, group B: mild-stimulation group). The medication, embryo status and pregnancy outcomes were compared between the two groups. Results Initiation dose of Gn, total Gn dose, HCG dose on trigger day in group A were significantly higher than those in group B(P < 0.05); LH on HCG day in group A was lower than that in group B( P < 0.05). The number of eggs, embryos and high quality embryos in group A were higher than those in group B( P < 0.05). Conclusion The clinical outcomes of the PPOS group were better than the mild-stimulation group. -
Key words:
- IVF/ICSI /
- Diminished ovarian reservee /
- Mild stimulation protocol /
- PPOS protocal
-
表 1 2组患者临床基线情况比较(M ± Q)
Table 1. Comparison of clinic data between the two groups (M ± Q)
指标 A组(n = 47) B组(n = 247) Z P 年龄(岁) 39.00 ± 7.00 40.00 ± 6.00 −0.969 0.332 不孕年限(a) 3.00 ± 4.00 3.00 ± 4.00 −0.555 0.579 BMI (kg/m2) 23.20 ± 3.80 22.90 ± 4.40 −0.368 0.713 bFSH(mIU/mL) 10.16 ± 5.46 9.47 ± 4.58 −0.246 0.806 bLH(mIU/mL) 4.63 ± 2.87 4.78 ± 2.91 −0.161 0.872 bE2 (pg/mL) 35.51 ± 24.79 36.12 ± 23.63 −0.137 0.891 bT(ng/mL) 0.20 ± 0.13 0.18 ± 0.15 −1.225 0.221 AFC 4.00 ± 3.00 3.00 ± 3.00 −2.753 0.060 AMH (ng/mL) 0.68 ± 0.86 0.48 ± 0.68 −2.003 0.054 TSH (mIU/L) 2.93 ± 2.43 2.59 ± 1.76 −1.439 0.150 表 2 2组患者临床促排卵过程比较(M ± Q)
Table 2. Comparison of ovulation induction outcomes between the two groups (M ± Q)
指标 HCG日LH(mIU/mL) HCG日E2(pg/mL) HCG日P(ng/mL) 获卵数(枚) 获胚数(枚) 优胚数(枚) A组(n=47) 3.30 ± 5.28 1277 ±1186 0.31 ± 0.3 3.00 ± 3.00 2.00 ± 2.00 1.00 ± 2.00 B组(n=247) 6.98 ± 7.90 903.2 ± 860.4 0.49 ± 0.44 2.00 ± 2.00 1.00 ± 2.00 1.00 ± 1.00 Z −4.733 −1.823 −3.336 −3.371 −2.961 −2.030 P < 0.001 * 0.068 0.001* 0.001* 0.003* 0.042* *P < 0.05。 表 3 2组患者冷冻胚胎移植的临床妊娠率比较[n(%)]
Table 3. Comparison of clinical pregnancy rates between the two groups [n(%)]
分组 周期数 临床妊娠率 χ2 P A组 27 7(25.9) 0.056 0.813 B组 147 35(23.8) -
[1] 张婉玉,李静,张凌寒,等. 卵巢储备功能下降的不孕症女性抗苗勒管激素与体重指数的相关性研究[J]. 生殖医学杂志,2021,30(4):441-446. doi: 10.3969/j.issn.1004-3845.2021.04.005 [2] 刘亚丽,于莎,陈秋菊,等. 克罗米芬联合高孕激素促排卵抑制早发LH峰的临床结局研究[J]. 生殖与避孕,2016,36(4):263-269. [3] Chen M,Wu Y,Huang X,et al. Embryo incubation by time-lapse systems versus conventional incubators in Chinese women with diminished ovarian reserve undergoing IVF/ICSI:A study protocol for a randomised controlled trial[J]. BMJ Open,2020,10(11):038657. [4] Pelosi E,Simonsick E,Forabosco A,et al. Dynamics of the ovarian reserve and impact of genetic and epidemiological factors on age of menopause[J]. Biol Reprod,2015,92(5):130. [5] Greenead,Patounakis G,Segars J H. Genetic associations with diminished ovarian reserve:A systematic review of the literature[J]. J Assist Reprod Genet,2014,31(8):935-946. doi: 10.1007/s10815-014-0257-5 [6] Yu R,Jin H,Huang X F,et al. Comparison of modified agonist,mild-stimulation and antagonist protocols for in vitro fertilization in patients with diminished ovarian reserve[J]. J Int Med Res,2018,46(6):2327-2337. doi: 10.1177/0300060518770346 [7] Kuang Y,chen Q,FU Y,et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization[J]. Fertil Steril,2015,104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022 [8] Wang Y,Kuang Y,Chen Q,et al. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment:Study protocol for a randomised controlled trial[J]. Trials,2018,19(1):455. doi: 10.1186/s13063-018-2850-x [9] 刘洋,南燕,陈帆,等. 不同促排卵方案在高龄卵巢储备功能减退患者中的应用效果比较[J]. 新乡医学院学报,2020,37(5):465-470. [10] 曾倩凌,燕怡,李艳萍,等. 高孕激素状态下促排卵与微刺激方案在卵巢储备功能下降患者中的临床结局及经济效益比较[J]. 中国临床研究,2020,33(7):908-912. doi: 10.13429/j.cnki.cjcr.2020.07.010 [11] Ubaldi F M,Cimadomo D,Vaiarelli A,et al. Advanced maternal age in IVF:Still a challenge? The present and the future of its treatment[J]. Front Endocrinol (Lausanne),2019,20(10):94. [12] Drakopoulos P, Bardhi E, Boudry L, et al. Update on the management of poor ovarian response in IVF: The shift from Bologna criteria to the Poseidon concept[J]. Ther Adv Reprod Health, 2020 , 31(14): 2633494120941480. [13] Liu X,Li T,Wang B,et al. Mild stimulation protocol vs conventional controlled ovarian stimulation protocol in poor ovarian response patients:A prospective randomized controlled trial[J]. Arch Gynecol Obstet,2020,301(5):1331-1339. doi: 10.1007/s00404-020-05513-6 [14] Casano S,Guidetti D,Patriarca A,et al. MILD ovarian stimulation with GnRH-antagonist vs. long protocol with low dose FSH for non-PCO high responders undergoing IVF:A prospective,randomized study including thawing cycles[J]. J Assist Reprod Genet,2012,29(12):1343-1351. doi: 10.1007/s10815-012-9863-2 [15] 沈秀,李颂军,周睿琼,等. 高孕激素下促排卵方案用于 FSH 升高DOR患者的临床效果观察[J]. 生殖医学杂志,2017,26(4):351-356. doi: 10.3969/j.issn.1004-3845.2017.04.012 [16] 中华医学会妇产科学分会绝经学组. 早发性卵巢功能不全的激素补充治疗的专家共识[J]. 中华妇产科杂志,2016,51(12):881-886. [17] Li X,Zhang X,Cai J,et al. Granulosa cells apoptosis and follicular fluid hormones:Comparison of progestin-primed ovarian stimulation versus GnRH antagonist protocols[J]. Gynecol Endocrinol,2021,37(7):609-613. doi: 10.1080/09513590.2020.1822802 [18] 温国亮. 不孕症患者冷冻胚胎移植后妊娠结局的影响因素[J]. 当代医学杂志,2022,28(21):129-131. [19] Salehnia M,Zavareh S. The effects of progesterone on oocyte maturation and embryo development[J]. Int J Fertil Steril,2013,7(2):74-81.